Mogamulizumab‐associated rash simulating lupus miliaris disseminatus faciei

Mitteldorf, Christina; Langer, N.; Kempf, Werner; Schön, Margarete

doi:10.1111/jdv.18741

Cited by 5 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the MAVORIC trial, mogamulizumab-associated rash (MAR) has been reported as the second most common adverse event [ 60 , 61 ]. Numerous reports in the literature have contributed to depicting such types of adverse events/effects [ 82 , 83 , 84 , 85 , 86 , 87 ]. Our group was the first to describe an MAR in 2018.…”

Section: The Developed and Under-investigation Treatments To Address ...mentioning

confidence: 99%

“…In most of the paper, it is stressed that MAR is difficult to distinguish from a CTCL relapse at a skin examination. At the same time, immunohistology provides clues for MAR diagnosis (presence of peculiar infiltrate as mentioned above and the expression of pan-T-cell markers such as CD7 and polyclonal TCR) [ 82 , 83 , 84 , 85 , 86 , 87 ].…”

Section: The Developed and Under-investigation Treatments To Address ...mentioning

confidence: 99%

“…Apart from the most common MAR presentation, sporadic cases of MAR presenting as lupus miliaris facei [ 84 ], alopecic lesions [ 82 , 86 ], and sebaceous hyperplasia eruption [ 88 ] have been reported in the literature. All the reported experiences strongly agree that MAR development is more common in SS and related to a better clinical outcome [ 4 , 82 , 83 , 84 , 85 , 86 , 87 , 89 , 90 , 91 ]. Such a finding is not trivial and should be associated with a direct action on neoplastic cells (i.e., apoptosis of tumour cells) and the decrease in immune suppressive cells (Treg cells).…”

Section: The Developed and Under-investigation Treatments To Address ...mentioning

confidence: 99%

Section: Mogamulizumab-associated Rashmentioning

confidence: 99%

See 3 more Smart Citations

A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments

Zengarini,

Guglielmo,

Mussi

et al. 2024

Antibodies

View full text Add to dashboard Cite

The CCR4 receptor is a pivotal target in cutaneous T-cell lymphoma (CTCL) therapy due to its role in impairing immune responses against malignant T-cells and expression profiles. Monoclonal antibodies like mogamulizumab effectively bind to CCR4, reducing tumour burden and enhancing patient outcomes by inhibiting the receptor’s interaction with ligands, thereby hindering malignant T-cell migration and survival. Combining CCR4 antibodies with chemotherapy, radiation, and other drugs is being explored for synergistic effects. Additionally, small-molecular inhibitors, old pharmacological agents interacting with CCR4, and CAR-T therapies are under investigation. Challenges include drug resistance, off-target effects, and patient selection, addressed through ongoing trials refining protocols and identifying biomarkers. Despite advancements, real-life data for most of the emerging treatments are needed to temper expectations. In conclusion, CCR4-targeted therapies show promise for CTCL management, but challenges persist. Continued research aims to optimise treatments, enhance outcomes, and transform CTCL management. This review aims to elucidate the biological rationale and the several agents under various stages of development and clinical evaluation with the actual known data.

show abstract

Section: The Developed and Under-investigation Treatments To Address ...mentioning

confidence: 99%

Section: The Developed and Under-investigation Treatments To Address ...mentioning

confidence: 99%

Section: The Developed and Under-investigation Treatments To Address ...mentioning

confidence: 99%

Section: Mogamulizumab-associated Rashmentioning

confidence: 99%

See 2 more Smart Citations

A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments

Zengarini,

Guglielmo,

Mussi

et al. 2024

Antibodies

View full text Add to dashboard Cite

show abstract

“…9 Zudem wurden kürzlich neue Erscheinungsformen des MAR, wie die palmoplantare Hyperkeratose, sowie Einzelfälle seltener Formen beschrieben, wie eine Lupus miliaris disseminatus faciei imitierende Form. 11,12 Die anatomische Verteilung des MAR ist sehr variabel und kann lokalisiert oder generalisiert sein. 9 Am häufigsten ist die Kopf-Hals-Region betroffen, oftmals mit ausschließlichem Befall der Kopfhaut, gefolgt von Rumpf und Extremitäten.…”

Section: Introductionunclassified

Mogamulizumab‐assoziierter Rash – Fallserie und aktuelle Literatur

Hansen,

Abeck,

Menz

et al. 2024

J Deutsche Derma Gesell

View full text Add to dashboard Cite

ZusammenfassungDer CC‐Chemokinrezeptor‐4‐Antikörper Mogamulizumab ist zur Zweitlinientherapie der Mycosis fungoides und des Sézary‐Syndroms zugelassen. Zu den häufigsten Nebenwirkungen gehört der Mogamulizumab‐assoziierte Rash (MAR), der sich klinisch sowie histologisch vielgestaltig präsentieren kann. Rein klinisch ist der MAR häufig nicht von einem Progress der Grunderkrankung zu unterscheiden, weshalb der histologischen Untersuchung eine wegweisende Rolle, im Rahmen der klinisch‐pathologischen Korrelation, zukommt. In bisherigen Datenanalysen finden sich Hinweise, dass der MAR häufiger bei Patienten mit Sézary‐Syndrom auftritt und mit einem signifikant besseren Therapieansprechen einhergeht, weshalb die Abgrenzung von einem Krankheitsprogress besonders relevant ist. Die Behandlung des MAR erfolgt in Abhängigkeit vom Schweregrad, eine Pausierung der Therapie mit Mogamulizumab kann notwendig sein.Wir präsentieren drei Fälle aus unserer Klinik sowie den aktuellen Wissensstand der Literatur und möchten damit die hohe Relevanz der Kenntnis über den MAR im Management von Patienten mit kutanen Lymphomen aufzeigen.

show abstract

Quoi de neuf en dermatologie clinique ?

Beylot-Barry

2023

Annales de Dermatologie et de Vénéréologie - FMC

View full text Add to dashboard Cite

Mogamulizumab‐associated rash simulating lupus miliaris disseminatus faciei

Cited by 5 publications

References 6 publications

A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments

A Narrative Review of the State of the Art of CCR4-Based Therapies in Cutaneous T-Cell Lymphomas: Focus on Mogamulizumab and Future Treatments

Mogamulizumab‐assoziierter Rash – Fallserie und aktuelle Literatur

Quoi de neuf en dermatologie clinique ?

Contact Info

Product

Resources

About